Mankind Pharma stock surges 4.5% as Q2 profit jumps 39%, revenue rises 17%

What happened

Mankind Pharma shares closed at Rs 2,312, gaining 4.5 percent, after the company reported a 39.2 percent year-on-year rise in net profit to Rs 712 crore and a 17.3 percent increase in revenue to Rs 4,338 crore for the second quarter.

Confirmed

Global impact / market context

Profit growing faster than sales means the company kept more profit from each sale, which can support its stock price because investors often pay more for companies that are becoming more efficient and profitable over time.

Analyst inference

The stock is up 6.8 percent in 2026 while the Nifty 50 has fallen 13.1 percent, so money has favoured this defensive drug maker over the broader market during a weak period for large Indian shares.

Analyst inference

What to watch

1. The company reported an operating profit margin, which means the share of revenue left after running costs, of 27 percent, up 210 basis points, and investors will watch whether this higher profitability is sustained. Confirmed
2. Investors should compare future quarterly sales growth with the 17.3 percent pace reported now, since slower growth could weaken the case for the stock's premium. Proposed
3. If the broader Nifty 50 keeps falling, funds may keep moving toward profitable drug makers, which could support the stock even without fresh company news. Analyst inference

Evidence

• Original source link unavailable